The SU2C Phillip A. Sharp Innovation in Collaboration Awards aim to foster synergistic and innovative collaborations among SU2C scientists. The inaugural awards will support five grants totaling $950,000, focusing on projects that enhance the SU2C mission to accelerate cancer treatment development.
The Farrah Fawcett Foundation is supporting a new $1.2 million research team to develop vaccines and immunotherapies for HPV-driven cancers, which currently have few therapeutic options. The team aims to identify tumor targets, activate specific immune cells, and deploy them at the tumor site for selective destruction of cancer.
A Dream Team led by Elizabeth Jaffee and Robert Vonderheide aims to exploit patients' own immune cells to treat pancreatic cancer. The team will use vaccination and other agents to activate antitumor immune cells and convert the tumor microenvironment into a fostered rejection environment.